Nataliya V. Uboha, MD, PhD, University of Wisconsin Carbone Cancer Center

Articles

ESMO 2021 Updates in Gastric Cancer and Colorectal Cancer

December 6th 2021

Sam Klempner, MD; Daniel H. Ahn, DO; Nataliya V. Uboha, MD, PhD; and Manish A. Shah, MD, FASCO, review recent updates in second-line gastric cancer, CAR T-cell therapy in solid tumors, and colorectal cancer presented at ESMO 2021.

ESMO 2021 Updates in HER2+ Metastatic Gastric and Gastroesophageal Cancer

November 29th 2021

Key opinion leaders in gastric cancers comment on ESMO 2021 updates in metastatic HER2+ esophagogastric adenocarcinoma and metastatic HER2+ gastric or gastroesophageal junction cancer.

ESMO 2021 Updates in Gastroesophageal and Gastric Adenocarcinomas

November 22nd 2021

Drs Sam Klempner, Nataliya V. Uboha, Daniel H. Ahn, and Manish A. Shah discuss recent data presented at ESMO 2021 for metastatic or locally advanced gastroesophageal and gastric adenocarcinomas.

ESMO 2021 Updates in Metastatic Esophageal Squamous Cell Carcinoma

November 15th 2021

Experts in gastrointestinal cancers review recent updates and clinical implications from phase 3 trials presented at ESMO 2021 in metastatic esophageal squamous cell carcinoma (ESCC).

Defining Oligometastatic Gastroesophageal Cancer May Provide Clarity for Treatment Advances

June 30th 2021

The debate continues as to how to define oligometastatic disease and whether it represents a unique stage between limited-stage and widely metastatic disease.

Dr. Uboha on Early Efficacy Data With Zanidatamab in HER2+ Upper GI Cancers

May 5th 2021

Nataliya V. Uboha, MD, PhD, discusses early efficacy data demonstrated with zanidatamab in HER2-expressing upper gastrointestinal cancers.